Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 601–700 of 1,000

Nonlinear dynamics in tumor-immune system interaction models with delays
Ruan, S. (2020) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2020282 · Cited by 45
Tumor microenvironment‐regulating nanomedicine design to fight multi‐drug resistant tumors
Xu, Q., Lan, X., Lin, H., Xi, Q., Wang, M., Quan, X., Yao, G., Yu, Z., Wang, Y., & Yu, M. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1842 · Cited by 45
IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice
Thomas, E. D., Meza‐Perez, S., Bevis, K. S., Randall, T. D., Gillespie, G. Y., Langford, C. P., & Alvarez, R. D. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0282-3 · Cited by 43
Effects of thymic selection on T cell recognition of foreign and tumor antigenic peptides
George, J. T., Kessler, D. A., & Levine, H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708573114 · Cited by 41
“I strategies, which can, in principle, evolve with a growing malignancy, have gained recent popularity for treating a variety of cancer types (1, 2).”
Background
Immunotherapy for Breast Cancer: Current and Future Strategies
Williams, A. D., Payne, K. K., Posey, A. D., Hill, C., Conejo-Garcia, J. R., June, C. H., & Tchou, J. C. (2017) · Current Surgery Reports · doi:10.1007/s40137-017-0194-1 · Cited by 43
Is it true that gut microbiota is considered as panacea in cancer therapy?
Farrokhi, A. S., Darabi, N., Yousefi, B., Askandar, R. H., Shariati, M., & Eslami, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28333 · Cited by 43
The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer “Omics”
Ciocan, C. A., Jurj, A. M., Buse, M., Gulei, D., Braicu, C., Ráduly, L., Cojocneanu, R., Pruteanu, L.-L., Iuga, C. A., Coza, O. F., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102576 · Cited by 43
Construction of Enzyme Nanoreactors to Enable Tumor Microenvironment Modulation and Enhanced Cancer Treatment
Liu, X., Hao, Y., Popovtzer, R., Feng, L., & Liu, Z. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001167 · Cited by 44
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation
Köhler, N., Ruess, D. A., Kesselring, R., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634435 · Cited by 45
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Antonarelli, G., Giugliano, F., Corti, C., Repetto, M., Tarantino, P., & Curigliano, G. (2021) · Pharmaceuticals · doi:10.3390/ph14090884 · Cited by 46
The Promise of Preventive Cancer Vaccines
Lollini, P., Cavallo, F., Nanni, P., & Quaglino, E. (2015) · Vaccines · doi:10.3390/vaccines3020467 · Cited by 43
“Only very recently have promising results from a handful of clinical trials modified the cancer vaccination landscape [20], which is now entering a new era [28].”
Background
Cancer Immunity: Lessons From Infectious Diseases
Trinchieri, G. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv070 · Cited by 41
“many of which are based on the use of monoclonal antibodies to tumor antigens and to immune regulators [6].”
Background
β-Glucan enhances cytotoxic T lymphocyte responses by activation of human monocyte-derived dendritic cells via the PI3K/AKT pathway
Ding, J., Feng, T., Ning, Y., Li, W., Wu, Q., Qian, K., Wang, Y., & Qi, C. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.01.009 · Cited by 44
“Recently, new approaches in immunotherapy offer hope of prolonged survival in cancer patients [1].”
From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells
Eshhar, Z. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2532 · Cited by 43
“the advances made in Cancer Immunotherapy as the breakthrough of the year (Couzin-Frankel, 2013).”
Antineoplastic activity of novel thiazole derivatives
Finiuk, N. S., Hreniukh, V. P., Ostapiuk, Y. V., Matiychuk, V. S., Frolov, D. A., Obushak, M. D., Stoika, R. S., & Babsky, A. M. (2017) · Biopolymers and Cell · doi:10.7124/bc.00094b · Cited by 44
Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach
Kakwere, H., Ingham, E. S., Allen, R. P., Mahakian, L. M., Tam, S. M., Zhang, H., Silvestrini, M. T., Lewis, J. S., & Ferrara, K. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00502 · Cited by 44
Amatuximab and novel agents targeting mesothelin for solid tumors
Baldo, P., & Cecco, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145105 · Cited by 37
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma
Ji, H., Niu, X., Yin, L., Wang, Y., Huang, L. J., Xuan, Q., Li, L., Zhang, H., Li, J., Yang, Y., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487288 · Cited by 41
Regulation of PD-1 in T cells for cancer immunotherapy
Yu, X., Gao, R., Li, Y., & Zeng, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173240 · Cited by 45
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
van Tilburg, C. M., Witt, R., Heiss, M., Pajtler, K. W., Plass, C., Poschke, I. C., Platten, M., Harting, I., Sedlaczek, O., Freitag, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07008-8 · Cited by 42
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
Marcq, E., Pauwels, P., van Meerbeeck, J. P., & Smits, E. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.006 · Cited by 41
Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 44
Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors
Xian, S., Chen, X., Ren, S., Chen, X., & Wang, H. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3511 · Cited by 41
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma
Wang, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.326 · Cited by 41
Gastric cancer management: Kinases as a target therapy
Farran, B., Müller, S., & Montenegro, R. C. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12743 · Cited by 41
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
Wu, X., Shaikh, A. B., Yu, Y., Li, Y., Ni, S., Lü, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091851 · Cited by 42
PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
Sun, X., Yan, X. H., Zhuo, W., Gu, J., Zuo, K., Liu, W., Liang, L., Gan, Y., He, G., Wan, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071984 · Cited by 41
Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis
Wei, Y., Du, Q., Jiang, X., Li, L., Li, T., Li, M., Fan, X., Li, Y., Kariminia, S., & Li, Q. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.008 · Cited by 39
Use of immunotherapy in the treatment of gastric cancer (Review)
Yang, L., Wang, Y., & Wang, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.10935 · Cited by 44
Moving Beyond the Pillars of Cancer Treatment: Perspectives From Nanotechnology
Siamof, C. M., Goel, S., & Cai, W. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.598100 · Cited by 41
“The immune system has limited natural ability to fight cancer, and the TME is often marked by immunosuppressive and immune-evasive mechanisms (Couzin-Frankel, 2013).”
Background
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
Behrens, L. M., van den Berg, T. K., & van Egmond, M. (2022) · Cancers · doi:10.3390/cancers14143366 · Cited by 43
“Immunotherapy focuses on stimulating the patient’s own immune system and recruits immune cells to kill tumor cells [3].”
Background
Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma
Tsukagoshi, M., Wada, S., Yokobori, T., Altan, B., Ishii, N., Watanabe, A., Kubo, N., Saito, F., Araki, K., Suzuki, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12853 · Cited by 41
Overcoming physical stromal barriers to cancer immunotherapy
Chung, S. W., Xie, Y., & Suk, J. S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01036-y · Cited by 46
The SysteMHC Atlas v2.0, an updated resource for mass spectrometry-based immunopeptidomics
Huang, X., Gan, Z., Cui, H., Lan, T., Liu, Y., Caron, É., & Shao, W. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1068 · Cited by 40
Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid–octadecylamine conjugate
Sun, J., Song, Y., Lu, M., Lin, X., Liu, Y., Zhou, S., Su, Y., & Deng, Y. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.029 · Cited by 40
Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds
Li, D., Sun, F., Bourajjaj, M., Chen, Y., Pieters, E. H. E., Chen, J., van den Dikkenberg, J. B., Lou, B., Camps, M. G. M., OSSENDORP, F. A., et al. (2016) · Nanoscale · doi:10.1039/c6nr05583d · Cited by 40
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
He, Y., Bunn, P. A., Zhou, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13486 · Cited by 40
Using MRI cell tracking to monitor immune cell recruitment in response to a peptide‐based cancer vaccine
Tremblay, M., Davis, C., Bowen, C. V., Stanley, O., Parsons, C., Weir, G., Karkada, M., Stanford, M. M., & Brewer, K. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27018 · Cited by 40
Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Agonists as Potential Small Molecule Therapeutics for Cancer Immunotherapy
Qiu, R., & Wang, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01314 · Cited by 45
The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies
Fruhwirth, G. O., Kneilling, M., de Vries, I. J. M., Weigelin, B., Srinivas, M., & Aarntzen, E. H. J. G. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1254-3 · Cited by 42
Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors
Song, W., Das, M., Xu, Y., Si, X., Zhang, Y., Tang, Z., & Chen, X. (2019) · Materials Today Nano · doi:10.1016/j.mtnano.2019.100029 · Cited by 41
Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona
Mikelez-Alonso, I., Aires, A., & Cortajarena, A. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020519 · Cited by 41
Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors
Dacoba, T. G., Anfray, C., Mainini, F., Allavena, P., Alonso, M. J., Andón, F. T., & Crecente‐Campo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01412 · Cited by 41
Cold Atmospheric Plasma Treatment for Pancreatic Cancer–The Importance of Pancreatic Stellate Cells
Verloy, R., Privat‐Maldonado, A., Smits, E., & Bogaerts, A. (2020) · Cancers · doi:10.3390/cancers12102782 · Cited by 40
“Immunotherapy was stated to be the biggest breakthrough in cancer research in 2013 [81] and is also actively used in research for PDAC [82], but to date, its efficacy in PDAC is still limited [83].”
Method
Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response
Khani, A. T., Sharifzad, F., Mardpour, S., Hassan, Z. M., & Ebrahimi, M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.014 · Cited by 42
Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy
Deng, Z., Wang, N., Ai, F., Wang, Z., & Zhu, G. (2020) · Open Research (University of Surrey) · doi:10.1002/viw.20200030 · Cited by 40
Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity
Persano, S., Das, P., & Pellegrino, T. (2021) · Cancers · doi:10.3390/cancers13112735 · Cited by 41
“These findings have provided the basis for the development of novel cancer therapeutics; however, such complex mechanisms are still a matter of study and pertain to the medical breakthroughs started i the l st decade, but which still hold great promise [3].”
Background
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Fu, Y., Peng, Y., Zhao, S., Mou, J., Zeng, L., Jiang, X., Yang, C., Huang, C., Li, Y., Yin, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689727 · Cited by 40
“Breakthroughs related to cancer immunotherapies have become a promising approach to cure cancer based upon the success of ICB (Couzin-Frankel, 2013; Baumeister et al., 2016; Kaiser and Couzin-Frankel, 2018).”
BackgroundInfluential
PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
Wang, Y., Zheng, K., Xiong, H., Huang, Y., Chen, X., Zhou, Y., Qin, W., Su, J., Chen, R., Qiu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762989 · Cited by 42
A plant-expressed conjugate vaccine breaks CD4+ tolerance and induces potent immunity against metastatic Her2+ breast cancer
Chotprakaikiat, W., Allen, A., Minh, D. B., Harden, E. L., Jobsri, J., Cavallo, F., Gleba, Y. Y., Stevenson, F. K., Ottensmeier, C. H. H., Klimyuk, V. I., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1166323 · Cited by 39
“In the last two decades immunotherapy has evolved into a breakthrough therapeutic modality for combating cancer.(1) Passive monoclonal antibodies (Mabs) targeting antigens on cancer cells or stimulating antitumor immunity through the release of blocking signals on T cells have shown significant clinical benefits, exte…”
Background
Implications of Tumor–Immune Coevolution on Cancer Evasion and Optimized Immunotherapy
George, J. T., & Levine, H. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.005 · Cited by 40
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
Tanaka, K., Chamoto, K., Saeki, S., Hatae, R., Ikematsu, Y., Sakai, K., Ando, N., Sonomura, K., Kojima, S., Taketsuna, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0021 · Cited by 41
“INTRODUCTION Development of immune checkpoint inhibitors (ICIs) such as those that target programmed cell death–1 (PD-1) or its ligand PD-1 ligand 1 (PD-L1) has had a profound impact on the treatment of various cancer types including lung cancer (1, 2).”
Background
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
“Immunotherapy is a targeted cancer treatment that utilizes a patient’s own immune system to eliminate cancer cells [409].”
Cryopreservation in the Era of Cell Therapy: Revisiting Fundamental Concepts to Enable Future Technologies
Bai, B., Xue, C., Wen, Y., Lim, J., Le, Z., Shou, Y., Shin, S., & Tay, A. K. P. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303373 · Cited by 39
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Katz, M. H. G., Petroni, G. R., Bauer, T. W., Reilley, M. J., Wolpin, B. M., Stucky, C., Bekaii‐Saab, T., Elias, R., Merchant, N. B., Costa, A. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007586 · Cited by 41
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39
Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade
Mei, J., Cai, Y., Xu, R., Li, Q., Chu, J., Luo, Z., Sun, Y., Shi, Y., Xu, J., Li, D., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12538 · Cited by 37
“NSCLC is one of the most progressive cancer types, and NSCLC patients exhibit a notable enhancement in survival and quality of life through the application of ICB [48–50].”
Background
Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells
Andón, F. T., & Alonso, M. J. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1073295 · Cited by 39
“dimension is gaining increasing importance, as noted by the fact that ‘‘Cancer Immunotherapy’’ was considered ‘‘the breakthrough of the year 2013’’ by the journal Science [20], and a full issue on this topic was published in April 2015 [21].”
Background
RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?
Conde, J., Arnold, C. E., Tian, F., & Artzi, N. (2015) · Materials Today · doi:10.1016/j.mattod.2015.07.005 · Cited by 39
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
Nelde, A., Kowalewski, D. J., Backert, L., Schuster, H., Werner, J.-O., Klein, R., Kohlbacher, O., Kanz, L., Salih, H. R., Rammensee, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316438 · Cited by 40
The Adaptive Complexity of Cancer
Derbal, Y. (2018) · BioMed Research International · doi:10.1155/2018/5837235 · Cited by 41
“Immunotherapy is another therapeutic modality ushered withmuchoptimism [6], butwhose curative potential has not been translated into concrete clinical benefits to the majority of patients due to cancer resistance to therapy [7].”
Background
pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy
Zhang, Y., Shen, T., Zhou, S., Wang, W., Lin, S., & Zhu, G. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000083 · Cited by 40
Patient expectations are better for immunotherapy than traditional chemotherapy for cancer
Ihrig, A., Richter, J., Grüllich, C., Apostolidis, L., Horak, P., Villalobos, M., Grapp, M., Friederich, H., & Maatouk, I. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03336-1 · Cited by 40
“The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients’ Lives (Williams 2019) or Breakthrough of the year: Cancer Immunotherapy (Couzin-Frankel 2013)) can raise high expectations.”
Background
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
Jiménez-Reinoso, A., Nehme-Álvarez, D., Domínguez-Alonso, C., & Álvarez‐Vallina, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.593848 · Cited by 38
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 46
“endogenous antitumor immunity against cancers via several directions.(53) Therefore, immunotherapy seeks to fortify components of the immune systems and modulate the complexity of the hostile tumor microenvironment (TME) such that”
Background
The Immune Landscape of Colorectal Cancer
Mezheyeuski, A., Micke, P., Martín-Bernabé, A., Backman, M., Hrynchyk, I., Hammarström, K., Ström, S., Ekström, J., Edqvist, P.-H. D., Sundström, M., et al. (2021) · Cancers · doi:10.3390/cancers13215545 · Cited by 39
“The introduction of immune checkpoint inhibitors has demonstrated that cancer immunity can be modified, leading to immune-mediated long-lasting tumor regression in subsets of patients with several different solid tumor types [9].”
Background
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Wang, H., Wang, Z.-G., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27175607 · Cited by 41
“In 2013, Science ranked tumor immunotherapy in the top 10 scientific breakthroughs, and immunotherapy is expected to be the next generation of tumor treatment after surgery, chemotherapy, and radiotherapy [29].”
Background
Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 40
Computational modelling of modern cancer immunotherapy
Valentinuzzi, D., & Jeraj, R. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abc3fc · Cited by 34
Secreted Factors by Anaplastic Thyroid Cancer Cells Induce Tumor-Promoting M2-like Macrophage Polarization through a TIM3-Dependent Mechanism
Stempin, C. C., Geysels, R. C., Park, S., Palacios, L. M., Volpini, X., Motrán, C. C., Rodríguez, E. V. A., Nicola, J. P., Cheng, S.-Y., Pellizas, C. G., et al. (2021) · Cancers · doi:10.3390/cancers13194821 · Cited by 38
Cancer immunotherapies: A hope for the uncurable?
Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 41
Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
Ratajczak, K., Grel, H., Olejnik, P., Jakieła, S., & Stobiecka, M. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115644 · Cited by 38
Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems
Peng, J., Li, S., & Ti, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s457782 · Cited by 42
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology
Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 41
Newly Recruited CD11b+, GR-1+, Ly6Chigh Myeloid Cells Augment Tumor-Associated Immunosuppression Immediately following the Therapeutic Administration of Oncolytic Reovirus
Clements, D. R., Sterea, A. M., Kim, Y., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402132 · Cited by 38
Intravital and Whole-Organ Imaging Reveals Capture of Melanoma-Derived Antigen by Lymph Node Subcapsular Macrophages Leading to Widespread Deposition on Follicular Dendritic Cells
Moalli, F., Proulx, S. T., Schwendener, R. A., Detmar, M. J., Schlapbach, C., & Stein, J. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00114 · Cited by 37
Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis
Kaye, E. C., Baker, J. N., & Broniscer, A. (2014) · CNS Oncology · doi:10.2217/cns.14.47 · Cited by 38
Optical In Vivo Imaging of the Alarmin S100A9 in Tumor Lesions Allows for Estimation of the Individual Malignant Potential by Evaluation of Tumor–Host Cell Interaction
Becker, A., Hokamp, N. G., Zenker, S., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146688 · Cited by 38
“Tumor immunotherapy, the strategy to inhibit the induction of tumor-promoting immune cells and consecutively increase the host ability to overcome the suppression of an effective antitumor immune response, has been hailed a turning point in cancer therapy (25).”
Background
The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development
Sistare, F. D., Mattes, W. B., & LeCluyse, E. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw025 · Cited by 39
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
Sun, R., Champiat, S., Dercle, L., Aspeslagh, S., Álvarez, E. C., Limkin, E. J., Baldini, C., Postel-Vinay, S. C., Hollebecque, A., Massard, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.033 · Cited by 39
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
Hebb, J. P. O., Mosley, A. R., Vences‐Catalán, F., Rajasekaran, N., Rosén, A., Ellmark, P., & Felsher, D. W. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2059-y · Cited by 38
“Immune checkpoint therapy has been a breakthrough in cancer treatment with survival benefits for several types of advanced malignancies [3, 4].”
Toward precision manufacturing of immunogene T-cell therapies
Xu, J., Melenhorst, J. J., & Fraietta, J. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.12.007 · Cited by 38
Tumor Regression and Cure Depends on Sustained Th1 Responses
Dai, M., Hellström, I., Yip, Y. Y., Sjögren, H. O., & Hellström, K. E. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000231 · Cited by 38
Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy
Rashidijahanabad, Z., & Huang, X. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101390 · Cited by 38
Therapeutic exploitation of neutrophils to fight cancer
Gruijs, M., Sewnath, C. A. N., & van Egmond, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101581 · Cited by 41
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer
Marrugal, Á., Ojeda, L., Paz-Ares, L. G., Molina‐Pinelo, S., & Ferrer, I. (2016) · Disease Markers · doi:10.1155/2016/2138627 · Cited by 38
Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy
Peng, S., Hou, X., Liu, J., & Huang, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.056 · Cited by 39
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
Goldberg, J. L., & Sondel, P. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.012 · Cited by 36
New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer
Verma, J., Monk, B. J., & Wolfson, A. H. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.05.003 · Cited by 37
Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene
Sheikhsaran, F., Sadeghpour, H., Khalvati, B., et al. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.11.008 · Cited by 37
Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma
Arbab, A. S., Rashid, M. H., Angara, K., Borin, T. F., Lin, P., Jain, M., & Achyut, B. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122732 · Cited by 38
“Immune therapies are a powerful strategy that inhibits tumor growth through enhancing immune responses inhibit tumor growth [134,135].”
Background
T lymphocytes against solid malignancies: winning ways to defeat tumours
Caruana, I., Simula, L., Locatelli, F., & Campello, S. (2018) · Cell Stress · doi:10.15698/cst2018.07.148 · Cited by 37
DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy
Kawai, M., Nakamura, T., Miura, N., Maeta, M., Tanaka, H., Ueda, K., Higashi, K., Moribe, K., Tange, K., Nakai, Y., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.08.006 · Cited by 37
Toll‐like receptors: A pathway alluding to cancer control
Ayala‐Cuellar, A. P., Cho, J., & Choi, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28879 · Cited by 38
Functional T cell activation by smart nanosystems for effective cancer immunotherapy
Yang, W., Zhou, Z., Lau, J., Hu, S., & Chen, X. S. (2019) · Nano Today · doi:10.1016/j.nantod.2019.05.004 · Cited by 37
Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis
Eng, J. R., Thibault, G., Luoh, S., Gray, J. W., Chang, Y. H., & Chin, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_24 · Cited by 35
In situ self-assembly of conjugated polyelectrolytes for cancer targeted imaging and photodynamic therapy
Khatoon, S. S., Chen, Y., Zhao, H., Lv, F., Liu, L., & Wang, S. (2020) · Biomaterials Science · doi:10.1039/c9bm01912j · Cited by 36
Recent insight into functional crystalline porous frameworks for cancer photodynamic therapy
Feng, J., Ren, W.-X., Kong, F., & Dong, Y. (2020) · Inorganic Chemistry Frontiers · doi:10.1039/d0qi01051k · Cited by 37
Influence of immunomodulatory drugs on the gut microbiota
Cohen, I., Ruff, W. E., & Longbrake, E. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.009 · Cited by 39
Evoking pyroptosis with nanomaterials for cancer immunotherapy: Current boom and novel outlook
Sun, Z., & Wang, W.-D. (2022) · Nano TransMed · doi:10.26599/ntm.2022.9130001 · Cited by 36

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks